02.01.2015 Views

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Table 4.6.4 Abdominoplasty.<br />

Author<br />

Year<br />

Reference<br />

Country<br />

Study<br />

design<br />

Population<br />

characteristics<br />

Intervention<br />

Method<br />

Number indi<strong>vid</strong>uals<br />

Control<br />

Number<br />

indi<strong>vid</strong>uals<br />

Results<br />

Withdrawal<br />

Drop outs<br />

Study quality<br />

and relevance<br />

Comments<br />

Sevin<br />

2007<br />

[2]<br />

Turkey<br />

RCT<br />

Abdominoplasty<br />

operated 2000.<br />

Average age: 37 years<br />

(27–47)<br />

Average BMI: 35 (28–42).<br />

n=207<br />

Follow-up at least<br />

3 times<br />

I1: Pre-op cephalosporin 1 g iv<br />

or levofloxacin 500 mg iv (n=69)<br />

I2: Pre-op cephalosporin 1 g iv<br />

or levofloxacin 500 mg iv and postop<br />

cephalosporin (2 x 1 g iv) for<br />

3 days or levofloxacin 500 mg x 1 iv<br />

for 3 days (n=69)<br />

C: No antibiotics<br />

(n=69). Comparable<br />

groups with respect<br />

to age, BMI, smoking,<br />

diabetes, vascular<br />

disease, previous<br />

abdominal surgery,<br />

steroid use<br />

Infection rate<br />

I1: 3/69 (4.3%),<br />

3/69 (4.3%)<br />

I2: 6/69 (8.7%),<br />

7/69 (10.1%).<br />

C: 9/69 (13%).<br />

Significant higher<br />

than I1 and I2<br />

p

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!